LivaNova wins FDA approval for aura6000 in sleep apnea

CURRENT BRIEF VERSION: LivaNova has won US FDA premarket approval for its aura6000 system, an implanted hypoglossal nerve stimulation device for adults with moderate to severe obstructive sleep apnea who have failed, can’t tolerate, or aren’t eligible for standard therapies such as positive airway pressure, oral appliances, or pharmacotherapy. The approval, granted on March 18, 2026, follows the company’s PMA submission in April 2025 and is backed by data from the OSPREY randomized controlled trial. In that study, LivaNova previously reported statistically significant primary safety and efficacy results, with median apnea-hypopnea index reduction of 66.2% and median oxygen desaturation index reduction of 63.3% at six months; at 12 months, the company said the active-treatment responder rate was 65%, with median reductions of 68% for both AHI and ODI. (accessdata.fda.gov)

Why it matters: For veterinary professionals tracking regulation and medtech, this is another sign that the FDA continues to support implantable neuromodulation platforms in sleep medicine, especially for patients who don’t do well with first-line therapy. The aura6000 approval also stands out because LivaNova and outside trade coverage have highlighted the device’s broader trial design, including patients at high risk of complete concentric collapse, a group often screened out of other hypoglossal nerve stimulation pathways. It also lands against a wider FDA backdrop for implantable neurotechnology: separately, Nia Therapeutics recently received Breakthrough Device designation for a fully implantable, closed-loop neurostimulation system for episodic memory loss after moderate to severe traumatic brain injury, underscoring continued agency openness to novel neuromodulation approaches beyond sleep medicine. That could matter for referral patterns, payer discussions, and competition in the sleep-device market. (accessdata.fda.gov)

What to watch: Next comes the commercial rollout, physician adoption, and any FDA post-approval study updates tied to PMA P250013. More broadly, the regulatory climate for implantable neuromodulation remains active, with companies such as Nia planning an IDE filing in 2026 for closed-loop systems in other neurologic indications. (accessdata.fda.gov)